Aug. 21, 2016
http://www.viartis.net/parkinsons.disease/news/160821.pdf
A nasal gel has been developed that can greatly increase the bioavailability of ropinirole.
Ropinirole (Requip), which is a dopamine agonist for the treatment of Parkinson's Disease
normally has low bioavailability when it is taken orally. For more information go to :
http://www.rxlist.com/requip-drug.htm
Thermoreversible nasal gels were prepared and formulations were evaluated for various
parameters such as gelling time, gelling temperature, gel strength, adhesive force, diffusion,
and bioavailability.
Formulations displayed gelling at nasal temperature and the
time was found to be less than the time taken to clear the
gel. The time the gel spent nasally increased due to
mucoadhesion and increased gel strength. The nasal gel
formulations showed drug release between 56% and 100%
within 5 hours. The gel also had a protective effect on the
mucosa unlike plain ropinirole which showed evidence of
moderate cellular damage.
The bioavailability of ropinirole in the brain was increased by five times when administered
nasally using the gel when compared to intravenous administration. Thermoreversible nasal
gel was consequently found to be a promising means of increased drug delivery for
Parkinson's Disease.
Reference : Drug Development and Industrial Pharmacy [2016] Aug 17 :1-34 [Epub ahead of
print] (M.Rao, D.K.Agrawal, C.Shirsath)
Complete abstract : http://www.ncbi.nlm.nih.gov/pubmed/27533244
http://www.viartis.net/parkinsons.disease/news/160821.pdf
No comments:
Post a Comment